Galectin Therapeutics Inc Unit Cons of 2 shs + 1 Wt
(NASDAQ : GALTU)

( )
GALTU PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.47%81.210.9%$648.72m
CELGCelgene Corporation
-10.76%121.331.1%$640.82m
AMGNAmgen Inc.
-0.63%182.961.1%$453.41m
BIIBBiogen Inc.
-1.26%338.101.2%$410.25m
REGNRegeneron Pharmaceuticals, Inc.
-1.81%432.982.7%$314.62m
VRTXVertex Pharmaceuticals Incorporated
0.02%154.631.9%$217.79m
INCYIncyte Corporation
-0.07%114.192.5%$202.03m
ALXNAlexion Pharmaceuticals, Inc.
-1.08%138.941.9%$183.38m
ALNYAlnylam Pharmaceuticals, Inc
-0.82%114.6810.7%$157.13m
EXELExelixis, Inc.
-1.06%27.176.5%$135.00m
ILMNIllumina, Inc.
2.29%209.883.5%$132.21m
BLUEBluebird Bio, Inc.
2.22%142.5517.3%$118.24m
BMRNBioMarin Pharmaceutical Inc.
-0.43%87.754.4%$113.37m
SRPTSarepta Therapeutics, Inc.
2.41%51.9416.9%$108.74m
CLVSClovis Oncology, Inc.
0.95%77.5016.5%$103.06m

Company Profile

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.